Global BCG Vaccine Market - 2022-2029

Market Overview

BCG Vaccine Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a highCAGR during the forecast period (2022-2029).

The only vaccine available to combat Tuberculosis is the Bacillus Calmette-Gurin (BCG) vaccine (TB). One dose is recommended for healthy babies near the time of birth in countries with a high incidence of Tuberculosis. However, only infants at high risk are usually immunized in areas where Tuberculosis is rare, while confirmed cases of Tuberculosis are personally screened and administered. It is also possible to immunize individuals who are not afflicted with Tuberculosis and who have not been recently immunized yet are also susceptible to drug-resistant Tuberculosis. The major factors propelling the growth of the BCG vaccine market are Increases in tuberculosis prevalence, especially in developing and underdeveloped countries, as well as technical developments in the field of vaccine research. Also, the rising birth rates across the globe, especially in China and India, contribute to the market's significant growth. Also, the rise in government policies and a global emphasis on immunization programs further drive demand growth. It is expected that untapped business opportunities in emerging regions can have multiple market growth prospects.

Market Dynamics: Increasing prevalence of Tuberculosis in developing and under-developed countries drives market growth

The increasing prevalence of Tuberculosis across the globe, especially in developing and under-developed countries such as India, China, and Africa, will stir the demand for the BCG vaccine as it is the only vaccine available for the disease. As per the global TB report 2020, most TB cases were in the WHO regions of South-East Asia (43%), Africa (25%) and the Western Pacific (18%), with smaller shares in the Eastern Mediterranean (8.3%), the Americas (3.0%) and Europe (2.3%). The 30 high TB burden countries accounted for 86% of all estimated incident cases worldwide, and eight of these countries accounted for two-thirds of the global total: India (26%), China (8.5%), Indonesia (8.4%), the Philippines (6.0%), Pakistan (5.8%), Nigeria (4.6%), Bangladesh (3.6%) and South Africa (3.3%). This high prevalence in emerging countries drives the market for BCG vaccines during the forecast period.

However, some side effects of the BCG vaccine adversely affect market growth. The side effects of the BCG vaccine among individuals are a key factor expected to curtail the global market's growth over the forecast period. Moreover, the shortage of supply in BCG vaccines in emerging countries is another factor expected to hinder the total market's growth in the near future. According to the American Urology Association, Merk and Company is the only producer of BCG in the United States informed the AUA that they were experiencing a global shortage of BCG due to the growing use and need for this product around the world. In comparison, Merck has raised the production of BCG as they expected the shortage of doses to carry through 2020.

Market Segmentation: The Immune BCG segment will project the fastest growth in the market throughout the forecast period

Based on the product, the BCG vaccine market has been classified into Immune BCG and Therapy BCG.

Immune BCG dominated the global market in 2021. Also, the Immune BCG is expected to present considerable growth shortly. BCG Vaccine is administered to newborns in the risk zone areas with a single dose of Immune BCG to prevent TB development. Therefore, the increasing usage of Immune BCG in the prevention of the development of TB is expected to propel segmental growth shortly.

BCG Vaccine is segmented on the basis of demographics, which includes Pediatrics (0-18 Years), Adults (19-35 Years).

The pediatrics (0-18 Years) segment held a significant market share in the forecast period. Pediatrics (0-18 Years) held the dominant position in the global market during the forecast period. In countries where the BCG vaccine is part of the national childhood immunization policy, BCG is normally offered to all children up to one year of age. In addition, older children (over 1 year of age) who have an elevated chance of contracting Tuberculosis should also be given this vaccine. It is rarely administered above 16 years of age and is never administered above 35 years of age since vaccines are only successful when administered at an early stage of life. It supports segment growth during the forecast period.

BCG Vaccine is segmented on the basis of Application, which includes Hospitals, Clinics, Others.

The hospital's segment held a significant market share in the forecast period. The administration of BCG vaccines done after the birth of a baby in the hospitals supports the segment growth during the forecast period. Moreover, the Clinics are expected to project a considerable CAGR during the forecast period. Older children (more than 1 year of age) who have an elevated risk of contracting Tuberculosis may also receive this vaccine administered at Clinics.

Geographical Penetration: Asia Pacific is the dominating region during the forecast period.

Based on geography, the study analyzes the BCG vaccine market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Asia Pacific region held a significant market share in the global BCG vaccine market in the forecast period. India is expected to represent considerable growth in Asia during the forecast period. In India, the prevalence of all forms of TB for all ages in India was 312 per lakh population in 2021, the highest prevalence for all forms of TB was 747 per lakh in Delhi, and the lowest was 137 per lakh population in Gujarat.

Moreover, the Middle East and Africa are expected to represent significant growth in value during the forecast period. BCG Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of tuberculosis cases in the region coupled with increasing government initiatives to combat the disease.

Competitive Landscape:

The BCG vaccine market is highly competitive, owing to the presence of major developments in vaccine production. The key BCG Vaccine players which are contributing to the growth of the global market include Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotech Group (a subsidiary of China National Pharmaceutical Group Corporation), Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute among others. The major players are adopting new product launches and expansion strategies for global growth in the BCG Vaccine market. In January 2021, Merk constructed a new facility in the United States to expand manufacturing capacity for Tice BCG. In July 2020, the Serum institute conducted a phase 3 clinical trial for the BCG vaccine. The Serum Institute of India is conducting a phase III clinical trial of BCG vaccine candidate VPM1002 to evaluate its ability to reduce infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age. In September 2020, the Serum Institute of India and Bill & Melinda Gates Foundation collaborated to make 100 million doses of COVID-19 vaccine available to low and middle-income countries. This collaboration provided upfront capital to Serum Institute of India to increase its manufacturing capacity. This collaboration majorly helps to boost the development of COVID-19 vaccines and ensure rapid, global access to them.

COVID-19 Impact: Negative impact on the global BCG vaccine market.

The outbreak of COVID-19 has negatively impacted the growth of the BCG vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development has led to de-escalation in BCG vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the BCG Vaccine market in 2020.

The global BCG vaccine market report would provide an access to approximately 55 market data tables, 49 figures and 170 pages